Sirolimus conversion after heart transplant: Risk factors for acute rejection and predictors of renal function response

A. Zuckermann, H. Eisen, S. See Tai, H. Li, C. Hahn, M. G. Crespo-Leiro

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

In a randomized, comparative study of cardiac transplant patients with mild-to-moderate renal insufficiency, conversion from calcineurin inhibitors (CNIs) to sirolimus improved renal function at 1 year versus continuing CNIs, with an attendant risk of biopsy-confirmed acute rejection (BCAR). Post hoc analyses were conducted to identify predictors of BCAR and GFR improvement associated with conversion. Patients with proteinuria >500 mg/day were excluded. Univariate and multivariate regression analyses tested 13 parameters for BCAR and six for GFR improvement. In 57 sirolimus-treated patients, mean daily mycophenolate mofetil (MMF) dose was lower in those with versus without BCAR (1000 vs. 1420 mg; p = 0.014). Receiver operating characteristic analysis identified MMF dose ≤1000 mg/day as the optimal cutoff to predict BCAR. Multivariate analysis confirmed low MMF dose (odds ratio: 9.94; p = 0.007) and non-white race (odds ratio: 15.3; p = 0.06) were independently associated with BCAR. GFR improvement was evaluated in intent-to-treat patients (n = 116). Significant interaction was detected between treatment effect and preexisting diabetes status (univariate p = 0.077; multivariate p = 0.022), indicating greater beneficial effect of sirolimus in those without preexisting diabetes. These findings suggest that sirolimus is more effective in improving GFR in patients without preexisting diabetes, and adequate MMF doses are needed for sirolimus conversion. This post hoc analysis of a 12-month, randomized, controlled, open-label trial in adult cardiac transplant patients with mild to moderate renal insufficiency finds that sirolimus was more effective in improving renal function in patients without preexisting diabetes, and that low mycophenolate mofetil dose and non-white race increased the risk of biopsy-confirmed acute rejection. See competing editorials by Patel (page 1960) and Kushwaha (page 1958).

Original languageEnglish (US)
Pages (from-to)2048-2054
Number of pages7
JournalAmerican Journal of Transplantation
Volume14
Issue number9
DOIs
StatePublished - Sep 2014

Fingerprint

Sirolimus
Mycophenolic Acid
Transplants
Kidney
Biopsy
Renal Insufficiency
Multivariate Analysis
Odds Ratio
Proteinuria
ROC Curve
Regression Analysis

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

Zuckermann, A. ; Eisen, H. ; See Tai, S. ; Li, H. ; Hahn, C. ; Crespo-Leiro, M. G. / Sirolimus conversion after heart transplant : Risk factors for acute rejection and predictors of renal function response. In: American Journal of Transplantation. 2014 ; Vol. 14, No. 9. pp. 2048-2054.
@article{7fe68c4f8a204e8da7fec925a42c2f9b,
title = "Sirolimus conversion after heart transplant: Risk factors for acute rejection and predictors of renal function response",
abstract = "In a randomized, comparative study of cardiac transplant patients with mild-to-moderate renal insufficiency, conversion from calcineurin inhibitors (CNIs) to sirolimus improved renal function at 1 year versus continuing CNIs, with an attendant risk of biopsy-confirmed acute rejection (BCAR). Post hoc analyses were conducted to identify predictors of BCAR and GFR improvement associated with conversion. Patients with proteinuria >500 mg/day were excluded. Univariate and multivariate regression analyses tested 13 parameters for BCAR and six for GFR improvement. In 57 sirolimus-treated patients, mean daily mycophenolate mofetil (MMF) dose was lower in those with versus without BCAR (1000 vs. 1420 mg; p = 0.014). Receiver operating characteristic analysis identified MMF dose ≤1000 mg/day as the optimal cutoff to predict BCAR. Multivariate analysis confirmed low MMF dose (odds ratio: 9.94; p = 0.007) and non-white race (odds ratio: 15.3; p = 0.06) were independently associated with BCAR. GFR improvement was evaluated in intent-to-treat patients (n = 116). Significant interaction was detected between treatment effect and preexisting diabetes status (univariate p = 0.077; multivariate p = 0.022), indicating greater beneficial effect of sirolimus in those without preexisting diabetes. These findings suggest that sirolimus is more effective in improving GFR in patients without preexisting diabetes, and adequate MMF doses are needed for sirolimus conversion. This post hoc analysis of a 12-month, randomized, controlled, open-label trial in adult cardiac transplant patients with mild to moderate renal insufficiency finds that sirolimus was more effective in improving renal function in patients without preexisting diabetes, and that low mycophenolate mofetil dose and non-white race increased the risk of biopsy-confirmed acute rejection. See competing editorials by Patel (page 1960) and Kushwaha (page 1958).",
author = "A. Zuckermann and H. Eisen and {See Tai}, S. and H. Li and C. Hahn and Crespo-Leiro, {M. G.}",
year = "2014",
month = "9",
doi = "10.1111/ajt.12833",
language = "English (US)",
volume = "14",
pages = "2048--2054",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "9",

}

Sirolimus conversion after heart transplant : Risk factors for acute rejection and predictors of renal function response. / Zuckermann, A.; Eisen, H.; See Tai, S.; Li, H.; Hahn, C.; Crespo-Leiro, M. G.

In: American Journal of Transplantation, Vol. 14, No. 9, 09.2014, p. 2048-2054.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Sirolimus conversion after heart transplant

T2 - Risk factors for acute rejection and predictors of renal function response

AU - Zuckermann, A.

AU - Eisen, H.

AU - See Tai, S.

AU - Li, H.

AU - Hahn, C.

AU - Crespo-Leiro, M. G.

PY - 2014/9

Y1 - 2014/9

N2 - In a randomized, comparative study of cardiac transplant patients with mild-to-moderate renal insufficiency, conversion from calcineurin inhibitors (CNIs) to sirolimus improved renal function at 1 year versus continuing CNIs, with an attendant risk of biopsy-confirmed acute rejection (BCAR). Post hoc analyses were conducted to identify predictors of BCAR and GFR improvement associated with conversion. Patients with proteinuria >500 mg/day were excluded. Univariate and multivariate regression analyses tested 13 parameters for BCAR and six for GFR improvement. In 57 sirolimus-treated patients, mean daily mycophenolate mofetil (MMF) dose was lower in those with versus without BCAR (1000 vs. 1420 mg; p = 0.014). Receiver operating characteristic analysis identified MMF dose ≤1000 mg/day as the optimal cutoff to predict BCAR. Multivariate analysis confirmed low MMF dose (odds ratio: 9.94; p = 0.007) and non-white race (odds ratio: 15.3; p = 0.06) were independently associated with BCAR. GFR improvement was evaluated in intent-to-treat patients (n = 116). Significant interaction was detected between treatment effect and preexisting diabetes status (univariate p = 0.077; multivariate p = 0.022), indicating greater beneficial effect of sirolimus in those without preexisting diabetes. These findings suggest that sirolimus is more effective in improving GFR in patients without preexisting diabetes, and adequate MMF doses are needed for sirolimus conversion. This post hoc analysis of a 12-month, randomized, controlled, open-label trial in adult cardiac transplant patients with mild to moderate renal insufficiency finds that sirolimus was more effective in improving renal function in patients without preexisting diabetes, and that low mycophenolate mofetil dose and non-white race increased the risk of biopsy-confirmed acute rejection. See competing editorials by Patel (page 1960) and Kushwaha (page 1958).

AB - In a randomized, comparative study of cardiac transplant patients with mild-to-moderate renal insufficiency, conversion from calcineurin inhibitors (CNIs) to sirolimus improved renal function at 1 year versus continuing CNIs, with an attendant risk of biopsy-confirmed acute rejection (BCAR). Post hoc analyses were conducted to identify predictors of BCAR and GFR improvement associated with conversion. Patients with proteinuria >500 mg/day were excluded. Univariate and multivariate regression analyses tested 13 parameters for BCAR and six for GFR improvement. In 57 sirolimus-treated patients, mean daily mycophenolate mofetil (MMF) dose was lower in those with versus without BCAR (1000 vs. 1420 mg; p = 0.014). Receiver operating characteristic analysis identified MMF dose ≤1000 mg/day as the optimal cutoff to predict BCAR. Multivariate analysis confirmed low MMF dose (odds ratio: 9.94; p = 0.007) and non-white race (odds ratio: 15.3; p = 0.06) were independently associated with BCAR. GFR improvement was evaluated in intent-to-treat patients (n = 116). Significant interaction was detected between treatment effect and preexisting diabetes status (univariate p = 0.077; multivariate p = 0.022), indicating greater beneficial effect of sirolimus in those without preexisting diabetes. These findings suggest that sirolimus is more effective in improving GFR in patients without preexisting diabetes, and adequate MMF doses are needed for sirolimus conversion. This post hoc analysis of a 12-month, randomized, controlled, open-label trial in adult cardiac transplant patients with mild to moderate renal insufficiency finds that sirolimus was more effective in improving renal function in patients without preexisting diabetes, and that low mycophenolate mofetil dose and non-white race increased the risk of biopsy-confirmed acute rejection. See competing editorials by Patel (page 1960) and Kushwaha (page 1958).

UR - http://www.scopus.com/inward/record.url?scp=84906275215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906275215&partnerID=8YFLogxK

U2 - 10.1111/ajt.12833

DO - 10.1111/ajt.12833

M3 - Article

C2 - 25307036

AN - SCOPUS:84906275215

VL - 14

SP - 2048

EP - 2054

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 9

ER -